Inactive Instrument

Highlights Prevail Therapeutics Inc.

Equities

PRVL

US74140Y1010

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Precision BioSciences, Inc. Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics	Apr. 16	CI
Eli Lilly and Company completed the acquisition of Prevail Therapeutics Inc. from Pontifax Ltd., OrbiMed Advisors LLC and others.	21-01-21	CI
Eli Lilly and : Lilly Raises 2020 Guidance, Sets 2021 Outlook -- Update	20-12-15	DJ
Eli Lilly and : Lilly Raises 2020 Guidance, Sets 2021 Outlook	20-12-15	DJ
Eli Lilly and : Lilly to Buy Prevail Therapeutics for Up to $1.04 Billion	20-12-15	DJ
Eli Lilly and Company entered into a definitive agreement to acquire Prevail Therapeutics Inc. from Pontifax Ltd., OrbiMed Advisors LLC and others for approximately $780 million.	20-12-14	CI
Prevail Therapeutics Inc. Announces First Patient Dosed in Phase 1/2 PROCLAIM Clinical Trial Evaluating PR006 for the Treatment of Frontotemporal Dementia Patients with GRN Mutations	20-12-11	CI
Prevail Therapeutics Inc. Receives European Commission Orphan Designation for PR006 for the Treatment of Frontotemporal Dementia	20-11-30	CI
Prevail Therapeutics Inc. Expects to Initiate Enrollment of the Phase 1/2 PROVIDE Clinical Trial of PR001 for Type 2 Gaucher Disease Patients in the Fourth Quarter of 2020	20-11-18	CI
Prevail Therapeutics Inc. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2020	20-11-13	CI
Prevail Therapeutics Receives U.S. FDA Fast Track Designation for PR001 for the Treatment of Neuronopathic Gaucher Disease	20-10-27	CI
Prevail Therapeutics Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2020	20-08-11	CI
Prevail Therapeutics to Highlight Multiple Gene Therapy Programs for Neurodegenerative Diseases At the Virtual 2020 Alzheimer’S Association International Conference	20-07-22	CI
Prevail Therapeutics Inc. Announces Unaudited Financial Results for the Quarter Ended March 31, 2020	20-05-14	CI
Prevail Therapeutics Inc. Announces Earnings Results for the Year Ended December 31, 2019	20-03-26	CI
Prevail Therapeutics Inc. Receives U.S. FDA Fast Track Designation for PR006 to Slow the Progression of Frontotemporal Dementia with a GRN Mutation	20-03-24	CI
Prevail Therapeutics Inc. Announces Investigational New Drug Application Active for PR006 for the Treatment of Frontotemporal Dementia with GRN Mutation	20-03-02	CI
Prevail Therapeutics Inc. Provides PR001 Program Update	20-01-09	CI
Prevail Therapeutics Inc. Announces IND Active for PR001 for Treatment of Neuronopathic Gaucher Disease	19-12-26	CI
Prevail Therapeutics Inc. Announces Earnings Results for the Third Quarter and Nine Months Ended September 30, 2019	19-11-12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Prevail Therapeutics Inc.

Equities

PRVL

US74140Y1010

Highlights

Filters